

## References

### I-238

1. Gidding S, Champagne M, de Ferranti S, et al. The agenda for familial hypercholesterolemia a scientific statement from the American Heart Association. *Circulat.* 2015;132(22): 2167–2192.
2. Arnett D, Blumenthal R, Albert M, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulat.* 2019;140(11): e563–e595.
3. Grundy S, Stone N, Bailey A, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol. *Circulat.* 2019;139:e1082–e1143.
4. Evkeeza™ (evinacumab-dgnb) injection, for intravenous use [package insert]. Regeneron Pharmaceuticals, Inc. Tarrytown, NY. Revised 02/2021.
5. Clinical Pharmacology™ Compendium. 2021. Tampa FL: Gold Standard, Inc. Evinacumab-dgnb.
6. Micromedex DrugDex Compendium®. 2021. Evinacumab-dgnb.
7. [Evinacumab-dgnb] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated [March 22, 2021].